SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Cream Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Mometasone Cream Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company: Organon & Co.
30 Hudson Street, 33nd floor
07302 Jersey City, New Jersey, U.S.A
Telephone: 551-430-6000
E-mail address of person responsible for the SDS: EHSSTEWARD@organon.com

1.4 Emergency telephone number
215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Skin irritation, Category 2: H315: Causes skin irritation.
Eye irritation, Category 2: H319: Causes serious eye irritation.
Long-term (chronic) aquatic hazard, Category 2: H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms:
Signal word: Warning
Hazard statements:
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H411 Toxic to aquatic life with long lasting effects.
Precautionary statements:
Prevention:
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ eye protection/ face protection.

Response:
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P391 Collect spillage.

Additional Labelling

EUH212 Warning! Hazardous respirable dust may be formed when used. Do not breathe dust.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2-Methyl-2,4-pentanediol</td>
<td>107-41-5 203-489-0 603-053-00-3</td>
<td>Skin Irrit. 2; H315 Eye Irrit. 2; H319</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td></td>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>Repr. 1B; H360Di STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 100</td>
<td>&gt;= 0.1 - &lt; 0.25</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.
SECTIONS 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Causes skin irritation. Causes serious eye irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Cream Formulation

Version 3.0
Revision Date: 09.04.2021
SDS Number: 1699540-00010
Date of last issue: 10.10.2020
Date of first issue: 21.05.2017

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting:
Vapours may form explosive mixtures with air. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides
Metal oxides

5.3 Advice for firefighters
Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions:
Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions:
Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Technical measures:
See Engineering measures under EXPOSURE
CONTROLS/PERSONAL PROTECTION section.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe vapours.
- Do not swallow.
- Do not get in eyes.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
- Keep in properly labelled containers. Keep tightly closed.
- Store in accordance with the particular national regulations.

Advice on common storage:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

7.3 Specific end use(s)

Specific use(s):
- No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>White mineral oil (petroleum)</td>
<td>8042-47-5</td>
<td>OELV - 8 hrs (TWA)</td>
<td>5 mg/m3</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(inhalable fraction)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Methyl-2,4-pentanediol</td>
<td>107-41-5</td>
<td>OELV - 15 min (STEL)</td>
<td>25 ppm 125 mg/m3</td>
<td>IE OEL</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>OELV - 8 hrs</td>
<td>4 mg/m3</td>
<td>IE OEL</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Cream Formulation

Version 3.0
Revision Date: 09.04.2021
SDS Number: 1699540-00010
Date of last issue: 10.10.2020
Date of first issue: 21.05.2017

Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used.

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>TWA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8919-23-7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Further information: Skin Wipe limit 10 µg/100 cm² Internal

These substance(s) are inextricably bound in the product and therefore do not contribute to a dust inhalation hazard.

Titanium dioxide

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-Methyl-2,4-pentanediol</td>
<td>Fresh water</td>
<td>0.429 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.043 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>4.29 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>20 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>1.59 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>0.159 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>0.066 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:
8.2 Exposure controls

**Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

**Personal protective equipment**

**Eye protection**
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**

**Material**
- Chemical-resistant gloves

**Remarks**
- Consider double gloving.

**Skin and body protection**
- Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

**Respiratory protection**
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Equipment should conform to I.S. EN 14387

**Filter type**
- Combined particulates and organic vapour type (A-P)

---

**SECTION 9: Physical and chemical properties**

**9.1 Information on basic physical and chemical properties**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>cream</td>
</tr>
<tr>
<td>Colour</td>
<td>white to off-white</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not classified as a flammability hazard</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
</tbody>
</table>
Mometasone Cream Formulation

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Vapours may form explosive mixture with air.
                      Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure:
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

2-Methyl-2,4-pentanediol:
- Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
- Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
  Method: OECD Test Guideline 402
  Assessment: The substance or mixture has no acute dermal toxicity

Mometasone:
- Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
- LD50 (Mouse): > 2,000 mg/kg
- Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Remarks: No mortality observed at this dose.
- LC50 (Mouse): > 3.2 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
    Application Route: Subcutaneous
    Symptoms: Breathing difficulties

Skin corrosion/irritation
Causes skin irritation.

Components:

2-Methyl-2,4-pentanediol:
Mometasone Cream Formulation

Result: Skin irritation
Remarks: Based on harmonised classification in EU regulation 1272/2008, Annex VI

Mometasone:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:
2-Methyl-2,4-pentanediol:
Species: Rabbit
Result: Irritation to eyes, reversing within 21 days

Mometasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
2-Methyl-2,4-pentanediol:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative

Mometasone:
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Assessment: Does not cause skin sensitisation.
Result: negative
Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.
Components:

2-Methyl-2,4-pentanediol:

Genotoxicity in vitro:

- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative

- Test Type: In vitro mammalian cell gene mutation test
  Method: OECD Test Guideline 476
  Result: negative

- Test Type: Chromosome aberration test in vitro
  Result: negative

Mometasone:

Genotoxicity in vitro:

- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative

- Test Type: Chromosomal aberration
  Test system: Chinese hamster lung cells
  Result: negative

- Test Type: Chromosomal aberration
  Test system: Chinese hamster ovary cells
  Result: positive

- Test Type: Mouse Lymphoma
  Result: negative

Genotoxicity in vivo:

- Test Type: Micronucleus test
  Species: Mouse
  Application Route: Oral
  Result: negative

- Test Type: Chromosomal aberration
  Species: Rat
  Cell type: Bone marrow
  Result: negative

- Test Type: unscheduled DNA synthesis assay
  Species: Rat
  Cell type: Liver cells
  Result: negative

Germ cell mutagenicity: Assessment

Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

Mometasone:

- Species: Rat
**SAFETY DATA SHEET**
according to Regulation (EC) No. 1907/2006

**Mometasone Cream Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.0</td>
<td>09.04.2021</td>
<td>1699540-00010</td>
<td>10.10.2020</td>
<td>21.05.2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Exposure time</th>
<th>Dose</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>2 Years</td>
<td>0.067 mg/kg body weight</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Dose</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>Inhalation</td>
<td>19 Months</td>
<td>0.160 mg/kg body weight</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Reproductive toxicity**
Not classified based on available information.

**Components:**

**2-Methyl-2,4-pentanediol:**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Reproduction/Developmental toxicity screening test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td>Application Route: Ingestion</td>
</tr>
<tr>
<td>Method: OECD Test Guideline 421</td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on foetal development</th>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td>Application Route: Ingestion</td>
</tr>
<tr>
<td>Method: OECD Test Guideline 414</td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

**Mometasone:**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td>Fertility: NOAEL: 0.015 mg/kg body weight</td>
<td>Symptoms: Reduced embryonic survival, Reduced foetal weight</td>
</tr>
<tr>
<td>Result: No effects on fertility, Effect on reproduction capacity</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on foetal development</th>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mouse</td>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight</td>
<td>Result: Embryotoxic effects., Teratogenicity and developmental toxicity</td>
</tr>
<tr>
<td>Test Type: Embryo-foetal development</td>
<td></td>
</tr>
<tr>
<td>Species: Rat</td>
<td>Application Route: Dermal</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight</td>
<td>Result: Embryo-foetal toxicity</td>
</tr>
<tr>
<td>Test Type: Embryo-foetal development</td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Cream Formulation

Species: Rabbit
Application Route: Dermal
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Subcutaneous
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Effects on newborn

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment:
Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure
Not classified based on available information.

Components:

Mometasone:

Remarks: Based on available data, the classification criteria are not met.

STOT - repeated exposure
Not classified based on available information.

Components:

Mometasone:

Exposure routes: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

2-Methyl-2,4-pentanediol:

Species: Rat
NOAEL: >= 450 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Method: OECD Test Guideline 408

Mometasone:
SAFETY DATA SHEET
according to Regulation (EU) No. 1907/2006

Mometasone Cream Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.0</td>
<td>09.04.2021</td>
<td>1699540-00010</td>
<td>10.10.2020</td>
</tr>
</tbody>
</table>

Species: Rat
NOAEL: 0.005 mg/kg
LOAEL: 0.3 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Dog
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Rat
NOAEL: 0.00013 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:

Mometasone:
Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

2-Methyl-2,4-pentanediol:

Eye contact: Target Organs: Eyes
Symptoms: Irritation
Mometasone Cream Formulation

SECTION 12: Ecological information

12.1 Toxicity

Components:

2-Methyl-2,4-pentanediol:

**Toxicity to fish**
- LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l
- Exposure time: 96 h

**Toxicity to daphnia and other aquatic invertebrates**
- EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l
- Exposure time: 48 h

**Toxicity to algae/aquatic plants**
- ErC50 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
- EC10 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

**Toxicity to microorganisms**
- NOEC: 200 mg/l
  - Exposure time: 10 d

Mometasone:

**Toxicity to fish**
- LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
  - Exposure time: 96 h
  - Remarks: No toxicity at the limit of solubility
- LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
  - Exposure time: 7 d
  - Remarks: No toxicity at the limit of solubility

**Toxicity to daphnia and other aquatic invertebrates**
- EC50 (Daphnia magna (Water flea)): > 5 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
  - Remarks: No toxicity at the limit of solubility
EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity): NOEC: 0.00014 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0.34 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity): 100

12.2 Persistence and degradability

Components:

2-Methyl-2,4-pentanediol:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 81 %
Exposure time: 28 d
Method: OECD Test Guideline 301F

Mometasone:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314
Mometasone Cream Formulation

12.3 Bioaccumulative potential

Components:

2-Methyl-2,4-pentanediol:
Partition coefficient: n-octanol/water : log Pow: 0
Remarks: Calculation

Mometasone:
Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water : log Pow: 4.68

12.4 Mobility in soil

Components:

Mometasone:
Distribution among environmental compartments : log Koc: 4.02

12.5 Results of PBT and vPvB assessment

Product:
Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### SECTION 14: Transport information

14.1 UN number or ID number

<table>
<thead>
<tr>
<th>ADN</th>
<th>UN 3077</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>UN 3077</td>
</tr>
<tr>
<td>RID</td>
<td>UN 3077</td>
</tr>
<tr>
<td>IMDG</td>
<td>UN 3077</td>
</tr>
<tr>
<td>IATA</td>
<td>UN 3077</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th>ADN</th>
<th>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)</td>
</tr>
<tr>
<td>RID</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)</td>
</tr>
<tr>
<td>IMDG</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)</td>
</tr>
<tr>
<td>IATA</td>
<td>Environmentally hazardous substance, solid, n.o.s. (Mometasone)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

| ADN | 9 |
| ADR | 9 |
| RID | 9 |
| IMDG| 9 |
| IATA| 9 |

14.4 Packing group

<table>
<thead>
<tr>
<th>ADN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group: III</td>
</tr>
<tr>
<td>Classification Code: M7</td>
</tr>
<tr>
<td>Hazard Identification Number: 90</td>
</tr>
<tr>
<td>Labels: 9</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Cream Formulation

Version 3.0  Revision Date: 09.04.2021  SDS Number: 1699540-00010  Date of last issue: 10.10.2020
Date of first issue: 21.05.2017

ADR
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments
Mometasone Cream Formulation

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

- REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
- REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
- REACH - List of substances subject to authorisation (Annex XIV): Not applicable
- Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
- Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
- Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

The components of this product are reported in the following inventories:
- AICS: not determined
- DSL: not determined
- IECSC: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

- H315: Causes skin irritation.
- H319: Causes serious eye irritation.
- H360Df: May damage the unborn child. Suspected of damaging fertility.
- H373: May cause damage to organs through prolonged or repeated exposure if inhaled.
- H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations
### Mometasone Cream Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.0</td>
<td>09.04.2021</td>
<td>1699540-00010</td>
<td>10.10.2020</td>
<td>21.05.2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Classification (STEL)</th>
<th>Classification (TWA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aquatic Chronic</td>
<td>Long-term (chronic) aquatic hazard</td>
</tr>
<tr>
<td>Eye Irrit.</td>
<td>Eye irritation</td>
</tr>
<tr>
<td>Repr.</td>
<td>Reproductive toxicity</td>
</tr>
<tr>
<td>Skin Irrit.</td>
<td>Skin irritation</td>
</tr>
<tr>
<td>STOT RE</td>
<td>Specific target organ toxicity - repeated exposure</td>
</tr>
<tr>
<td>IE OEL</td>
<td>Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Classification (STEL)</th>
<th>Classification (TWA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IE OEL / OELV - 8 hrs (TWA)</td>
<td>Occupational exposure limit value (8-hour reference period)</td>
</tr>
<tr>
<td>IE OEL / OELV - 15 min (STEL)</td>
<td>Occupational exposure limit value (15-minute reference period)</td>
</tr>
</tbody>
</table>

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICL - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:

<table>
<thead>
<tr>
<th>Skin Irrit. 2</th>
<th>H315</th>
<th>Calculation method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye Irrit. 2</td>
<td>H319</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Aquatic Chronic 2</td>
<td>H411</td>
<td>Calculation method</td>
</tr>
</tbody>
</table>
Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN